On May 19, 2025, Fractyl Health, Inc. announced that its groundbreaking gene therapy for patients with type 2 diabetes and obesity had achieved milestone progress, offering durable efficacy and safety with a single dose, along with limited systemic exposure to glucagon-like peptide-1 (GLP-1).Known as RJVA-001, this therapeutic approach is designed to target pancreatic cells and […]